RE:RE:RE:RE:RE:RE:RE:RE:QuestionsWhat analysts (lol)? Yes -- not one serious biotech or cancer analyst covers the stock. They are marginal tiny firms with zero following in the US. Guarantee you there is not one new PM looking at THTX this morning because of this. They need to rebuild that audience, get on to CNBC and get a bit of PR push around this in the general and business press and then, maybe, there's some recognition. If I were IR, I'd be calling FierceBiotech blog, Bloomberg, a wire service or two and pitching the story. Here's a brand new, novel cancer target for people that have nothing left, and while way to early, we saw signs it may be able to do in humans what we and the FDA saw from 2 years worth of pre-clinical work that got us fast-track. We're pushing that now. Here's the "stories" -- etc.... Someone will bite, but they need to go out and push it hard to get some PR and wider readership and thougth around this early and small bit of good news that really shows a lot around the potential.
Lldks1 wrote: From a looong time follower and first time poster - could the " not good enough" be that we've been waiting for this ( great?) news yet the share price ( and analysts attention) is meh????